The Effect Of Resuscitation Guided By Two Different Dynamic Parameters On Time To Normalization Of The Capillary Refill Time In Adult Patients With Septic Shock

NCT ID: NCT06122909

Last Updated: 2025-04-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-21

Study Completion Date

2025-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to compare the effect of resuscitation guided by Left ventricular outflow tract-velocity time integral (LVOT-VTI) variation versus the effect of resuscitation guided by inferior vena cava (IVC) variation on time to normalization of the capillary refill time in adult patients with septic shock, amount of resuscitation fluids, rate of vasopressor and ICU length of stay.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Capillary refill time will be measured by applying firm pressure to the ventral surface of the right index finger distal phalanx with a glass microscope slide. The pressure will be increased until the skin is blank and then maintained for 10 seconds. The time for return of the normal skin color will be registered with a chronometer. A CRT \> 3 seconds will be considered abnormal.

Patients with normal CRT at baseline will proceed to periodic monitoring (every hour/6 hours) and start the algorithm if CRT becomes abnormal at any of these timepoints. Patients with abnormal CRT will follow the loop when fulfilling the Sepsis-3 definition of septic shock.

Sepsis time 0 is defined as the time of admission to the ICU for sepsis treatment upon the inclusion criteria. For patients already in the ICU, sepsis time 0 is considered the earliest time at which the patients satisfy the inclusion criteria.

Fluid responsiveness FR will be assessed using a structured approach. Dynamic predictors of FR will be evaluated depending on the individual status, i.e., considering if under MV or spontaneous breathing, Vt, respiratory rate (RR), respiratory system compliance and the presence of arrhythmias.

Passive leg raise PLR is performed by tilting a patient from a 45-degree semi-recumbent head-up position to a 30-45° degree leg-up position or by lifting the legs passively from the horizontal position. This maneuver transfers up to 300 mL of blood from the lower limbs and the splanchnic territory into the intrathoracic compartment and induces significant changes in cardiac preload, mean systemic pressure and the upstream pressure of systemic venous return. It is reliable and can be implemented in either spontaneously breathing or mechanically ventilated patients and can often be repeated. A method that has been recommended by the Surviving Sepsis Campaign, and is appraised by the European Society of Intensive Care Medicine.

After informed consent is obtained from the caregiver, transthoracic two-dimensional 2D, M-mode, and Doppler echocardiography will be performed on commercially available echocardiographic equipment (Mindray, M7 Premium) using a (SP5-1s) probe. Echocardiography will be performed to measure the LVOT diameter measured in the long-axis parasternal view, and the time-velocity integral of the flow wave across the aortic valve (VTI) will be obtained by pulsed wave Doppler and averaged over the whole respiratory cycle. Synchronization of the measurements with the different times of the ventilatory cycle will be verified by insertion of a pressure signal.

For the spontaneously breathing patients, the images will be obtained over 1 respiratory cycle, inspiration and expiration will be defined by the biggest and smallest size, respectively. Multiple ECHO images will be obtained and the 3 most consistent will be averaged off-line.

LVOT-VTI variation and IVC diameter variation will be measured twice at least for every patient in both groups at baseline and post PLR. The 3 most consistent recordings will be chosen and averaged at baseline and post PLR for the sake of precision of values.

IVC Collapsibility diameter \< 21 mm and index ≥ 50% indicates fluid responsiveness in spontaneously breathing patients. IVC distensibility index \> 18% indicates fluid responsiveness in mechanically ventilated patients. Passive leg raising test \> 12% increase in SV indicates fluid responsiveness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock Resuscitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Left ventricular outflow tract-velocity time integral (LVOT-VTI) resuscitation based group Inferior vena cava (IVC) diameter variation resuscitation based group
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Both participants and outcome assessors will be blinded to the groups

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group VTI

Group VTI (n=45): will receive resuscitation guided by LVOT-VTI variation after PLR test.

Group Type EXPERIMENTAL

Group VTI

Intervention Type DRUG

Group VTI will receive resuscitation guided by LVOT-VTI variation after PLR test.

Group IVC

Group IVC (n=45): will receive resuscitation guided by IVC diameter variation after PLR test.

Group Type ACTIVE_COMPARATOR

Group IVC

Intervention Type DRUG

Group IVC will receive resuscitation guided by IVC diameter variation after PLR test.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Group VTI

Group VTI will receive resuscitation guided by LVOT-VTI variation after PLR test.

Intervention Type DRUG

Group IVC

Group IVC will receive resuscitation guided by IVC diameter variation after PLR test.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult patients ( ≥ 18 years) of either gender with septic shock according to the Sepsis-3

Exclusion Criteria

* Known history of any cardiac pathology, acute coronary syndrome, cardiac dysrhythmias (as a primary diagnosis), acute pulmonary edema or known poor systolic cardiac function (left ventricular ejection fraction \< 50%).
* Body mass index ≥ 35 kg/m2 .
* Concomitant acute respiratory distress syndrome) or high PEEP (\> 10 cmH2O) requirements on mechanical ventilation (MV).
* Child B or C liver cirrhosis.
* End-stage renal disease with or without dialysis.
* Pregnancy.
* Multi-organ system failure.
* Active hemorrhage.
* Head trauma.
* Intra-abdominal hypertension (\> 15 mmHg).
* Declined to consent.
Minimum Eligible Age

19 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mansoura University

OTHER

Sponsor Role collaborator

Kasr El Aini Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Khaled Abdelfattah Abdallah Sarhan

principal investigator, Asst. professor of anesthesia, Cairo university

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mansoura University, Central Hospital

Al Mansurah, Dakahlia Governorate, Egypt

Site Status

Cairo university hospitals, kasralainy

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MD ∕ 22.06.664

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.